Sutro Biopharma, Inc. revenue for the last year amounted to 62.04 M USD, the most of which — 62.04 M USD — came from its highest performing source at the moment, Site-specific and Novel-format Antibody Drug Conjugates, the year earlier bringing 153.73 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Sutro Biopharma, Inc. 62.04 M USD, and the year before that — 153.73 M USD.